ClinCalc Pro
Menu
Folate-receptor-α antibody-drug conjugate

Mirvetuximab soravtansine (Specialist drug)

Brand names: Elahere

Adult dose

Dose: Specialist initiation only — refer to BNF/SmPC
Route: IV
Frequency: every 3 weeks

Clinical pearls

  • Folate-receptor-α-positive platinum-resistant ovarian cancer; specialist oncology
  • Mandatory ophthalmic exam before each dose

Contraindications

  • Hypersensitivity

Side effects

  • Ocular toxicity (keratopathy, blurred vision)
  • Pneumonitis
  • Peripheral neuropathy
  • Cytopenias

Interactions

  • Live vaccines

Monitoring

  • Ophthalmic
  • FBC
  • Pulmonary symptoms
  • Neurological exam

Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/mirvetuximab-soravtansine-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.